Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewTenidap
说明： NSAID, cyclooxygenase (COX-1) inhibitor. Also opener of KIR2.3
别名： CP 66248
化学名： (Z)-5-Chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-1H-indole-1-carboxamide
纯度： ≥99% (HPLC)
生物活性 for Tenidap
Tenidap is a NSAID that preferentially inhibits COX-1 (IC50 values are < 0.03, 1.2 and > 30 μM for COX-1, COX-2 and 5-lipoxygenase respectively). Inhibits formation of pro-inflammatory arachidonic acid metabolites in isolated human peripheral polymorphonuclear leukocytes. Opener of inward rectifying hKir2.3 channel (EC50 = 402 nM).
化合物库 for Tenidap
Tenidap is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。
技术数据 for Tenidap
| 分子量 | 320.75 |
| 公式 | C14H9N2O3SCl |
| 储存 | Store at +4°C |
| 纯度 | ≥99% (HPLC) |
| CAS Number | 120210-48-2 |
| PubChem ID | 54683953 |
| InChI Key | LXIKEPCNDFVJKC-QXMHVHEDSA-N |
| Smiles | O=C1N(C(N)=O)C2=CC=C(Cl)C=C2/C1=C(O)\C3=CC=CS3 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for Tenidap
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| DMSO | 32.07 | 100 |
制备储备液 for Tenidap
以下数据基于产品分子量 320.75。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 3.12 mL | 15.59 mL | 31.18 mL |
| 5 mM | 0.62 mL | 3.12 mL | 6.24 mL |
| 10 mM | 0.31 mL | 1.56 mL | 3.12 mL |
| 50 mM | 0.06 mL | 0.31 mL | 0.62 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for Tenidap
参考文献 for Tenidap
参考文献是支持产品生物活性的出版物。
Moilanen et al (1988) CP-66,248, a new anti-inflammatory agent, is a potent inhibitor of leukotriene B4 and prostanoid synthesis in human polymorphonuclear leucocytes in vitro. Eicosanoids 1 35 PMID: 2856170
Kirchner et al (1997) Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation. J.Pharmacol.Exp.Ther. 282 1094 PMID: 9262379
Liu et al (2002) Tenidap, a novel anti-inflammatory agent, is an opener of the inwardly rectifying K+ channel hKir2.3. Eur.J.Pharmacol. 435 153 PMID: 11821021
If you know of a relevant reference for Tenidap, please let us know.
按标靶查看相关产品
按产品操作查看相关产品
关键词: Tenidap, Tenidap supplier, NSAID, cyclooxygenase, COX-1, inhibitors, inhibits, KIR23, openers, Cyclooxygenase, Oxygenases, Oxidases, Potassium, KIR, Channels, KATP, Inward, Rectifier, K+, CP66248, CP, 66248, rectifier, 2580, Tocris Bioscience
Tenidap 的评论
目前没有该产品的评论。 Be the first to review Tenidap and earn rewards!
Have you used Tenidap?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.